Migraine management continues to evolve with innovative medical devices leading the way. Among them, Relivion MG has showcased remarkable efficacy, especially evident in the RIME Pivotal Study. The study findings indicate that patients could achieve Complete Migraine Freedom (pain and MBS) at 2-hours post-treatment.

A key factor behind these results is Relivion MG’s distinctive engineering design that uniquely targets both the trigeminal and occipital pathways, offering a comprehensive approach to migraine relief. Relivion is the only neuromodulation device available that offers this concurrent stimulation.